Novartis CEO Vas Narasimhan expressed confidence in the company's long-term growth.

1 report, 1 independent Updated Jul 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Novartis

Keep exploring

Part of

Philippe Martin was named Viatris' chief R&D officer, while Novartis and Teva are noted for drug approvals and generic production. All 1 developments

The entities involved

Novartis
Swiss-American multinational pharmaceutical corporation
- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
- GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Coverage

Newest first; wire copies grouped

Jul 18BenzingaNovartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED) Editor’s Note: The title of the story has been corrected to reflect that the outl